RoosterBio was founded in 2013 with the intention to de-bottleneck and revolutionize the adult stem/stromal cell industry. RoosterBio launched manufacturing operations in October 2013 and started shipping cell and media products to customers in February 2014. We have 200+ customers worldwide: from North America to Europe to Asia. We are passionate about advancing regenerative medicine applications and adult cell therapies to the clinic.
Roosters proclaim the dawn of a new day, and RoosterBio is here to proudly proclaim the dawn of a new day in Biofabrication.
Our goal is to accelerate the biologics and biofabrication revolution much in the same way we are seeing 3D printers drive the local-maker movement. We believe that, if we drive the cost of stem/stromal cells from $1000 to $10 per million cells, we will see a large expansion of living stem cells used into next generation therapeutics, medical devices, and even consumer products.
Biofabrication is the creation of advanced biological models, medical therapeutic products, and non-medical biological systems.
Currently, the number and the growth of MSC trials are outpacing other cell sources. This is for several reasons.
Due to their tremendous therapeutic potential, the trend of MSC technology being incorporated into regenerative therapies will continue, and there is a strong need for affordable, abundant, and extremely well characterized MSC products to enable product development and successful clinical translation. New technologies such as bioprinting, cell and tissue engineering, synthetic biology/genetic manipulation, and of course, cell manufacturing sciences will continue to propel the field of Regenerative Medicine forward and further necessitate the need for the availability of large numbers (lot sizes in the billions) of clinically-translatable MSCs.